Touat, Mehdi
Li, Yvonne Y.
Boynton, Adam N.
Spurr, Liam F.
Iorgulescu, J. Bryan http://orcid.org/0000-0003-1405-3667
Bohrson, Craig L.
Cortes-Ciriano, Isidro
Birzu, Cristina
Geduldig, Jack E.
Pelton, Kristine
Lim-Fat, Mary Jane http://orcid.org/0000-0002-4317-5770
Pal, Sangita
Ferrer-Luna, Ruben
Ramkissoon, Shakti H.
Dubois, Frank
Bellamy, Charlotte
Currimjee, Naomi
Bonardi, Juliana
Qian, Kenin http://orcid.org/0000-0003-0296-6207
Ho, Patricia http://orcid.org/0000-0002-4622-8188
Malinowski, Seth
Taquet, Leon
Jones, Robert E.
Shetty, Aniket
Chow, Kin-Hoe
Sharaf, Radwa
Pavlick, Dean
Albacker, Lee A.
Younan, Nadia
Baldini, Capucine
Verreault, Maïté
Giry, Marine
Guillerm, Erell
Ammari, Samy
Beuvon, Frédéric
Mokhtari, Karima
Alentorn, Agusti
Dehais, Caroline
Houillier, Caroline
Laigle-Donadey, Florence
Psimaras, Dimitri
Lee, Eudocia Q.
Nayak, Lakshmi
McFaline-Figueroa, J. Ricardo
Carpentier, Alexandre
Cornu, Philippe
Capelle, Laurent
Mathon, Bertrand
Barnholtz-Sloan, Jill S. http://orcid.org/0000-0001-6190-9304
Chakravarti, Arnab
Bi, Wenya Linda
Chiocca, E. Antonio
Fehnel, Katie Pricola
Alexandrescu, Sanda
Chi, Susan N.
Haas-Kogan, Daphne
Batchelor, Tracy T.
Frampton, Garrett M.
Alexander, Brian M.
Huang, Raymond Y.
Ligon, Azra H.
Coulet, Florence
Delattre, Jean-Yves
Hoang-Xuan, Khê
Meredith, David M.
Santagata, Sandro http://orcid.org/0000-0002-7528-9668
Duval, Alex http://orcid.org/0000-0003-1534-1724
Sanson, Marc
Cherniack, Andrew D. http://orcid.org/0000-0003-0470-0111
Wen, Patrick Y.
Reardon, David A.
Marabelle, Aurélien
Park, Peter J. http://orcid.org/0000-0001-9378-960X
Idbaih, Ahmed
Beroukhim, Rameen http://orcid.org/0000-0001-6303-3609
Bandopadhayay, Pratiti
Bielle, Franck
Ligon, Keith L.
Article History
Received: 22 July 2019
Accepted: 4 March 2020
First Online: 15 April 2020
Competing interests
: M.T. reports consulting or advisory role for Agios Pharmaceutical, Integragen, and Taiho Oncology, outside the submitted work; travel, accommodations, expenses from Merck Sharp & Dome, outside the submitted work. Y.Y.L. reports equity from g.Root Biomedical. S.H.R., R.S., D. Pavliak, L.A.A., G.M.F. and B.M.A. report employment with Foundation Medicine and stock interests from Roche. K.M. reports advisory board honoraria from Bristol-Meyers Squibb, outside the submitted work. F.L.-D. reports fees from Pharmtrace, outside the submitted work. E.Q.L. reports consulting or advisory role for Eli Lilly; royalties from UpToDate; honoraria from Prime Oncology. L.N. reports consulting or advisory role for Bristol-Meyers Squibb, outside the submitted work. T.T.B. reports honoraria from Champions Oncology, UpToDate, Imedex, NXDC, Merck, GenomiCare Biotechnology; consulting or advisory role for Merck, GenomiCare Biotechnology, NXDC, Amgen; travel, accommodations, expenses from Merck, Roche, Genentech, GenomiCare Biotechnology. A.H.L. reports leadership from Travera (I); stock and other ownership interests from Travera (I); consulting or advisory role for Travera (I). K.H.-X. reports advisory board honoraria from Bristol-Meyers Squibb, outside the submitted work. S.S. reports personal fees from Rarecyte, outside the submitted work. P.Y.W. reports honoraria from Merck; consulting or advisory role for AbbVie, Agios Pharmaceuticals, AstraZeneca, Blue Earth Diagnostics, Eli Lilly, Genentech, Roche, Immunomic Therapeutics, Kadmon Corporation, KIYATEC, Puma Biotechnology, Vascular Biogenics, Taiho Pharmaceutical, Deciphera Pharmaceuticals, VBI Vaccines; speakers’ bureau from Merck, prIme Oncology; research funding from Agios Pharmaceuticals (Inst), AstraZeneca (Inst), BeiGene (Inst), Eli Lilly (Inst), Roche (Inst), Genentech (Inst), Karyopharm Therapeutics (Inst), Kazia Therapeutics (Inst), MediciNova (Inst), Novartis (Inst), Oncoceutics (Inst), Sanofi (Inst), Aventis (Inst), VBI Vaccines (Inst); travel, accommodations, expenses from Merck. D.A.R. reports honoraria from AbbVie, Cavion, Genentech, Roche, Merck, Midatech Pharma, Momenta Pharmaceuticals, Novartis, Novocure, Regeneron Pharmaceuticals, Stemline Therapeutics, Celldex, OXiGENE, Monteris Medical, Bristol-Myers Squibb, Juno Therapeutics, Inovio Pharmaceuticals, Oncorus, Agenus, EMD Serono, Merck, Merck KGaA, Taiho Pharmaceutical, Advantagene; consulting or advisory role for Cavion, Genentech, Roche, Merck, Momenta Pharmaceuticals, Novartis, Novocure, Regeneron Pharmaceuticals, Stemline Therapeutics, Bristol-Myers Squibb, Inovio Pharmaceuticals, Juno Therapeutics, Celldex, OXiGENE, Monteris Medical, Midatech Pharma, Oncorus, AbbVie, Agenus, EMD Serono, Merck, Merck KGaA, Taiho Pharmaceutical; research funding from Celldex (Inst), Incyte (Inst), Midatech Pharma (Inst), Tragara Pharmaceuticals (Inst), Inovio Pharmaceuticals (Inst), Agenus (Inst), EMD Serono (Inst), Acerta Pharma (Inst), Omnivox. A.I. reports grants and other from Carthera (September 2019); research grants from Transgene; grants from Sanofi, and Air Liquide; and travel funding from Leo Pharma, outside the submitted work. R.B. reports consulting or advisory role for Novartis, Merck (I), Gilead Sciences (I), ViiV Healthcare (I); research funding from Novartis; patents, royalties, other intellectual property—Prognostic Marker for Endometrial Carcinoma (US patent application 13/911456, filed June 6, 2013), SF3B1 Suppression as a Therapy for Tumors Harboring SF3B1 Copy Loss (international application No. WO/2017/177191, PCT/US2017/026693, filed July 4, 2017), Compositions and Methods for Screening Pediatric Gliomas and Methods of Treatment Thereof (international application No. WO/2017/132574, PCT/US2017/015448, filed 1/27/2017). P.B. reports research grants from the Novartis Institute of Biomedical Research; patents, royalties, other intellectual property—Compositions and Methods for Screening Pediatric Gliomas and Methods of Treatment Thereof (international application No. WO/2017/132574, PCT/US2017/015448, filed 1/27/2017). F. Bielle reports employment from Celgene (I); stocks from Crossject (I); research grants from Sanofi and Abbvie; travel, accommodations, expenses from Bristol-Myers Squibb for travel expenses, outside the submitted work. K.L.L. reports grants and personal fees from BMS, grants from Amgen, personal fees and other from Travera LLC, personal fees from InteraGen, personal fees from Rarecyte, grants from Tragara, grants from Lilly, grants from Deciphera, grants from X4, all outside the submitted work; and has patent US20160032359A1 pending. Inst. denotes institutional funding; I denotes a competing interest involving a first degree relative of the author. The other authors report no competing interests.